Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00183976 · ClinicalTrials.gov registry record · Phase 2
Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas
A Phase 2 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00183976 is a Phase 2 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 15 participants.
The verdict
NCT00183976, a Phase 2 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study is for patients who have been treated before and either the treatment did not work or the lymphoma has come back.
Interventions
- DRUG Pegylated Liposomal Doxorubicin (Doxil) and Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00183976
The ClinicalTrials.gov registry entry for NCT00183976 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pegylated Liposomal Doxorubicin (Doxil) and Rituximab is the first listed.
NCT00183976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00183976 about?
NCT00183976 is a clinical study titled "Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas". This study is for patients who have been treated before and either the treatment did not work or the lymphoma has come back.
What is the current status of trial NCT00183976?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2005-04. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00183976?
The interventions under investigation include: Pegylated Liposomal Doxorubicin (Doxil) and Rituximab (DRUG).
Who is sponsoring clinical trial NCT00183976?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.